Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment...
3 KB (128 words) - 00:21, 8 January 2024
Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab...
49 KB (6,229 words) - 07:45, 16 October 2024
necrosis factor related activation protein (TRAP) inflammatory diseases Lexatumumab mab human TRAIL-R2 cancer Libivirumab mab human hepatitis B surface antigen...
136 KB (4,079 words) - 00:12, 12 October 2024
levotofisopam (USAN) levoxadrol (INN) levoxyl levulan lexacalcitol (INN) lexapro lexatumumab (INN) lexgenleucel-T (USAN) lexipafant (INN) lexithromycin (INN) lexiva...
8 KB (379 words) - 05:02, 25 September 2024
Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab...
8 KB (501 words) - 13:55, 10 September 2024
vedotin† Intetumumab§ Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab#...
5 KB (368 words) - 15:29, 21 August 2024
Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab...
8 KB (316 words) - 13:53, 10 September 2024
Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab...
20 KB (2,146 words) - 16:24, 21 August 2024
Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab...
24 KB (2,809 words) - 11:12, 20 August 2024
therapeutics. This deal generated belimumab, raxibacumab, mapatumumab and lexatumumab. In April 2012, the first three of these products formed part of the...
11 KB (1,095 words) - 21:02, 24 August 2024
Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab...
12 KB (1,494 words) - 19:35, 4 September 2024
Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab...
12 KB (1,459 words) - 03:14, 30 October 2022
Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab...
12 KB (1,387 words) - 13:47, 4 September 2024
Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab...
12 KB (1,508 words) - 17:56, 19 August 2022
vedotin† Intetumumab§ Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab#...
4 KB (241 words) - 13:42, 14 July 2024
vedotin† Intetumumab§ Ipilimumab Iratumumab§ Istiratumab Icrucumab§ Lexatumumab§ Lucatumumab§ Mapatumumab§ Narnatumab§ Necitumumab Nesvacumab§ Nivolumab#...
3 KB (129 words) - 01:04, 19 July 2023
raxibacumab". Two anti-TRAIL receptor antibodies – mapatumumab (HGS-ETR1) and lexatumumab (HGS-ETR2). Early work by CAT and HGS scientists showed that HGS-ETR1...
91 KB (8,496 words) - 16:05, 19 August 2024
hepatocellular cancer, which accounts for 80-90% of all liver cancers." Lexatumumab Statement On A Nonproprietary Name Adopted By The Usan Council - Mapatumumab...
9 KB (751 words) - 21:40, 20 December 2023